AHP, based in Wayne, Pennsylvania, is a lower middle market private equity investor focused exclusively on healthcare. A division of Argosy Capital, AHP typically pursues majority control transactions ...

Ampersand Capital Partners has announced its acquisition of Nektar Therapeutics’ PEGylation reagent manufacturing business.

Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of its previously ...

PEGylation, the process of attaching polyethylene glycol (PEG) molecules to another compound, notably proteins or peptides, has gained considerable attention in the fields of biochemistry and ...

Innovations such as PEGylation and nanotechnology also play a role in optimizing PROTAC efficacy. These developments hold promise for safer, more effective cancer therapies, though challenges remain ...

PEGylation enhances the stability, solubility, and half-life of therapeutic proteins, leading to better efficacy and fewer side effects. Additionally, advancements in biologics and increasing R&D ...

In November, Nektar signed a definitive agreement with Ampersand Capital Partners to sell its commercial PEGylation Reagent manufacturing business in Huntsville, AL, for $90 million. The sale ...

S-Palmitoylation is the only reversible post-translational lipid modification. Knowledge about the DHHC palmitoyltransferase family is still limited. Here we show that human ZDHHC6, which modifies key ...